News
ADC Drugs Offer Hope for RET+ NSCLC Patients
In case you missed it, one promising report from ASCO 2023 offers hope to patients who may be looking for additional options after RET-TKI's. Telisotuzumab vedotin (teliso-v) is a new...
ADC Drugs Offer Hope for RET+ NSCLC Patients
In case you missed it, one promising report from ASCO 2023 offers hope to patients who may be looking for additional options after RET-TKI's. Telisotuzumab vedotin (teliso-v) is a new...
Unlocking the Promise of RET Fusions: A Game-Ch...
Let's talk about RET, a fascinating receptor tyrosine kinase protein with a vital role in our development and cell growth. While it's normally beneficial, when RET signaling goes awry, it...
Unlocking the Promise of RET Fusions: A Game-Ch...
Let's talk about RET, a fascinating receptor tyrosine kinase protein with a vital role in our development and cell growth. While it's normally beneficial, when RET signaling goes awry, it...
RET Research Update: Encouraging Findings Ahead!
We have some exciting RET-specific research grant updates to share! RET-positive's science advisors, Hilary Hammell and Nicolas LeBel, recently met with our 2021 grant awardees and have painstakingly reviewed their research progress reports. Here's what they...
RET Research Update: Encouraging Findings Ahead!
We have some exciting RET-specific research grant updates to share! RET-positive's science advisors, Hilary Hammell and Nicolas LeBel, recently met with our 2021 grant awardees and have painstakingly reviewed their research progress reports. Here's what they...
Claim Denials? Don't Panic! Unlock the Power of...
Every US state has a DOI. Among other matters, it is their responsibility to help you: Understand your insurance policy File a complaint or appeal with your insurance company Identify...
Claim Denials? Don't Panic! Unlock the Power of...
Every US state has a DOI. Among other matters, it is their responsibility to help you: Understand your insurance policy File a complaint or appeal with your insurance company Identify...
Our interview with RETexpert Dr. Tejas Patil
RETpositive is excited to introduce you to Tejas Patil, Assistant Professor, Medicine-Medical Oncology, University of Colorado, School of Medicine. Dr. Patil is a 2022 Lungevity/Hamoui Foundation awardee for his research on MET and EGFR...
Our interview with RETexpert Dr. Tejas Patil
RETpositive is excited to introduce you to Tejas Patil, Assistant Professor, Medicine-Medical Oncology, University of Colorado, School of Medicine. Dr. Patil is a 2022 Lungevity/Hamoui Foundation awardee for his research on MET and EGFR...
Research is Hope: Why We Fundraise
Our late founder, Aliye Bricker, MD, was diagnosed with Stage IV RET-positive NSCLC after giving birth to her second daughter at the age of 34. Aliye lived for another six...
Research is Hope: Why We Fundraise
Our late founder, Aliye Bricker, MD, was diagnosed with Stage IV RET-positive NSCLC after giving birth to her second daughter at the age of 34. Aliye lived for another six...